Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 Dosing, Need to Know Information, Safety, Stacks, Dosing Calculator and more!

How much do I take? Is this right for me? How do I use it? Is it safe? How do I know it's working? Compound Profile Scientific & Efficacy Data C62H98N16O22 Molecular Formula 1419.53 g/mol Molecular Weight 4-6 hours Half-Life ~100% (subcutaneous) Bioavailabilit

How much do I take?

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Compound Profile

Scientific & Efficacy Data

C62H98N16O22

Molecular Formula

1419.53 g/mol

Molecular Weight

4-6 hours

Half-Life

~100% (subcutaneous)

Bioavailability

137525-51-0

CAS #

9941444

PubChem ID ↗

Developed By · 1992

Predrag Sikirić

University of Zagreb

Primary Benefits

Accelerates wound healing

Promotes tendon repair

Promotes ligament repair

Amino Acid Sequence

Dosing

How muchdo I take?

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

Starting Dose

250 mcg

Frequency

Once daily

Duration

1-2 weeks

A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].

Standard Dose

250-500 mcg

Twice daily

4-6 weeks

Commonly used range for tissue and tendon recovery in research practice [1][3].

Advanced Dose

500 mcg

6-8 weeks

Upper end used in practice for more demanding acute injuries [1][3].

Timing

Best time to take

Administer at a consistent time each day. Consistency matters more than the specific time of day.

With food?

Food timing does not significantly affect absorption for injectable peptides.

If stacking

If combining BPC-157 with other peptides, space administrations by 15-30 minutes. Consult your healthcare provider before combining with prescription medications.

Adjusting Your Dose

Increase if

+Current dose is well-tolerated for 2+ weeks

+Desired effects not yet noticeable

+Healthcare provider recommends dose increase

Decrease if

-Side effects become bothersome or persistent

-Desired effects achieved at lower dose

-Healthcare provider recommends reduction

Signs of right dose

✓Noticeable improvement in target symptoms

✓Good tolerance with minimal side effects

✓Consistent positive response between doses

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Suitability

Is thisright for me?

Best For

Tendon and ligament injuries

Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair

Gut healing

IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue

Muscle injuries

Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression

Joint problems

Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties

Post-surgical recovery

Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms

Consider Alternatives If

Goal: Weight loss

Consider: Tirzepatide, Semaglutide

Goal: Growth hormone optimization

Consider: CJC-1295, Ipamorelin

Goal: Cognitive enhancement

Consider: Semax, Selank

Goal: Anti-aging / skin

Consider: GHK-Cu, Epithalon

Who Should Avoid

Do not use if

×Pregnancy

×Breastfeeding

×Active cancer

×History of cancer

Use with caution if

!You have any chronic medical conditions

!You are taking prescription medications

!You have a history of allergic reactions to peptides

Not Sure?

Compare BPC-157 with similar peptides to find the best fit for your goals.

Administration

How do Iuse it?

Reconstitution

What you need

•Bacteriostatic water (BAC water)

•Insulin syringes (29-31 gauge)

•Alcohol swabs

•Sharps container

Example

If using a standard vial, add bacteriostatic water to achieve your desired concentration. For example, adding 2mL of BAC water to a vial allows precise dosing with an insulin syringe.

Draw up the appropriate volume based on your reconstitution ratio. Consult dosing charts for exact volumes corresponding to 250-500 mcg doses.

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)

Best sites

•Lower abdomen (2 inches from navel)

•Outer thigh (middle third)

•Back of upper arm

Technique

1.Wash hands and prepare clean workspace

2.Clean injection site with alcohol swab

3.Draw correct dose into insulin syringe

4.Pinch skin and insert needle at 45-90 degree angle

5.Inject slowly, withdraw needle

6.Apply gentle pressure—do not rub

7.Dispose of syringe in sharps container

Storage

Before reconstitution

Store in refrigerator at 36-46°F (2-8°C). Keep in original packaging to protect from light. Do not freeze.

After reconstitution

Store reconstituted solution in refrigerator at 36-46°F (2-8°C). Use within 30 days. Do not freeze reconstituted solution.

Signs of degradation

Solution appears cloudy or discolored

Visible particles or precipitates in solution

Solution has changed color from original appearance

Vial has been exposed to temperatures above 77°F (25°C) for extended periods

Sample Daily Schedule

Morning (8:00 AM)

250mcg injection

Site: Near injury or abdomen

Administer via subcutaneous injection in the morning for consistency. Inject near the site of injury for optimal localized healing effects, or in the abdomen for systemic benefits.

Evening (8:00 PM)

Site: Rotate from morning

Duration: Continue for 4-6 weeks. Then: 2-4 week break before restarting if needed.

Safety

Is itsafe?

Safety Profile

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

BPC-157's evidence base is categorized as 'Strong preclinical' based on extensive rat models demonstrating accelerated healing across multiple tissue types including tendon, ligament, muscle, and GI mucosa. However, no completed Phase 3 human clinical trials exist. Published human data is limited to a small number of early-phase studies and case reports. Manufacturing quality varies significantly between suppliers as the compound is not regulated by the FDA.

Common Side Effects

Experienced by some users

Injection site redness

Usually resolves in 30-60 minutes

Management: Rotate sites, ice if needed

Mild nausea

Typically only first few doses

Management: Take with food, reduce dose temporarily

Dizziness

Rare, usually with higher doses

Management: Reduce dose, stay hydrated

Less Common

•Headache

•Fatigue

•Hot/cold sensations

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×If you experience severe or persistent injection site reactions or signs of infection

×If you develop signs of an allergic reaction such as difficulty breathing, swelling, or severe rash

×If healing progress plateaus after 6+ weeks of continuous use, indicating need for reassessment or alternative approaches

Always consult with a healthcare provider before discontinuing BPC-157, especially if used for active injury recovery. Do not stop abruptly without medical guidance as this may impact healing outcomes.

Interactions

With other peptides

✓TB-500

✓GHK-Cu

✓CJC-1295 + Ipamorelin

With medications

!Blood Thinners - Blood Thinners (Warfarin

!etc.) - etc.)

!NSAIDs - NSAIDs (Ibuprofen

With supplements

✓Vitamin D3 - Generally safe and may support overall health

✓Magnesium - Generally safe and may enhance peptide absorption

Effectiveness

Does itwork?

Evidence Level

Strong preclinical

What to Expect

Week 1-2

What you might notice

•Reduced inflammation

•Less pain at injury site

•Improved gut comfort (if used for digestive issues)

What's normal

•Subtle changes—don't expect dramatic results yet

•Some users feel nothing this early

What's next

→Continue protocol

→Maintain consistent timing

Week 3-4

•Noticeable improvement in injury healing

•Increased mobility

•Better function in affected area

•Significant gut symptom relief

•This is when most users see clear benefits

•Progress may be gradual, not sudden

→Assess if dose adjustment needed

→Continue if seeing progress

Week 5-6+

•Substantial or complete healing

•Return to normal activity

•Lasting improvements

•Healing timeline varies by injury severity

•Some chronic conditions need longer

→Consider stopping if healed

→Take 2-4 week break

→Can restart if needed

Signs It's Working

For injuries

✓Less pain at rest

✓Less pain with movement

✓Improved range of motion

✓Faster recovery between workouts

✓Reduced swelling

For gut issues

✓Less bloating

✓Reduced pain after eating

✓More regular digestion

✓Decreased symptoms overall

Not Seeing Results?

Common reasons

•Not allowing enough time—most peptides require consistent use for weeks to months before full effects are apparent

•Inconsistent dosing schedule—maintaining regular administration is critical for optimal results

•Improper storage or handling leading to degraded product

•Individual variation in response—genetics, health status, and other factors affect how you respond

•Dose may need adjustment—consult with your healthcare provider about optimizing your protocol

Key Research

[1]"BPC 157 and its role in healing"

Sikiric et al., 2018

Finding: Demonstrated healing across multiple tissue types including tendon, ligament, muscle, and gut lining with no observed toxicity.

[2]"Gastric pentadecapeptide BPC 157 and wound healing"

Seiwerth et al., 2014

Finding: Accelerated wound closure and tissue regeneration in multiple animal models.

[3]"Effect of BPC 157 on tendon healing"

Chang et al., 2011

Finding: Significantly improved tendon-to-bone healing in rat rotator cuff model.

Organ Targets

Powered by Human Organ Atlas

Organs and body systems affected by BPC-157, mapped to the Human Organ Atlas — an open-access 3D portal featuring 56 organs imaged at near-cellular resolution.

Stomach & GI Tract

Digestive System

Accelerates healing of gastric ulcers, repairs intestinal lining, and protects against NSAID-induced gut damage

Liver

Supports hepatoprotective effects and promotes liver tissue repair

Heart

Cardiovascular System

Promotes angiogenesis and supports cardiovascular tissue repair

Brain

Nervous System

Neuroprotective effects, supports dopaminergic and serotonergic systems

The Science

Stacking & Combinations

Frequently Asked Questions

How long does BPC-157 take to work?

Can I take BPC-157 orally?

Should I inject near the injury site?

Can I stack BPC-157 with other peptides?

Do I need to cycle BPC-157?

Technical Specifications

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 Studied ACL Injury Recovery — Formulations and Dosing Protocols

Rat Achilles Tendon Transection 10 μg/kg/day for 14 days Intraperitoneal injection Biomechanical strength recovery 72% faster recovery (p<0.01) Rabbit ACL Tear Subcutaneous injection Tensile strength and collagen deposition 68% greater strength, 40% more collagen Rat MCL Transection 10 μg/kg/day for 28 days Intramuscular injection near injury site Return to weight-bearing activity 6 days faster (40% reduction in timeline) Human Extrapolation (theoretical) 200–500 μg/day subcutaneous Not clinically validated N/A. No human trials completed Unknown. No data The theoretical human dose of 200–500 μg/day is based on allometric scaling from rodent studies, but this is speculative. No pharmacokinetic or safety data exists for humans at any dose. Athletes using BPC-157 during ACL recovery are participating in an uncontrolled, self-directed experiment with no medical oversight or adverse event tracking.
SIDE EFFECTS

What are the side effects of BPC-157?

Preclinical studies indicate that BPC-157 has a favorable safety profile with few reported side effects. However, comprehensive human trials are lacking, and potential side effects in humans are not well-documented (PMID 40005999).
02

Question drills

Open a question for its connected answer.

01Frequently Asked Questions About BPC-157+

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

SOURCE / peptidemind.com ↗
02What If the Lyophilised Powder Looks Slightly Yellow When the Vial Arrives?+

Discard the batch immediately without reconstituting. Yellow tint in BPC-157 indicates oxidative degradation of the tyrosine residues at positions 1 and 15, which are critical for receptor binding and biological activity. This degradation occurs when peptides are exposed to light, moisture, or temperatures above specification during storage or transit. The oxidised peptide will dissolve normally and appear fine after reconstitution, but bioactivity is already compromised.

SOURCE / realpeptides.co ↗
03What If I Need BPC-157 Delivered Quickly in Denver — How Fast Can I Receive It?+

Real Peptides processes all Denver orders same-day if placed before 2 PM Mountain Time, shipping via USPS Priority (2–3 business days) or FedEx Overnight (next business day for orders placed by noon). Most Denver, CO addresses in zip codes 80201–80205 receive standard Priority shipments within 48 hours. We provide tracking numbers within two hours of order confirmation, and all peptides ship in insulated packaging with cold packs during summer months to maintain stability.

SOURCE / realpeptides.co ↗
04What If I'm Already Taking Antibiotics — Can I Add the BPC-157 LL-37 Stack?+

Yes. The stack is designed to complement antibiotic therapy, not replace it. LL-37's antimicrobial mechanism (membrane disruption) differs from how antibiotics work (targeting bacterial ribosomes, cell walls, or metabolic pathways), meaning no direct pharmacological interference exists between the two. Research from the University of British Columbia found that LL-37 actually enhances antibiotic efficacy against biofilm-embedded bacteria by disrupting the protective matrix that shields them from drug penetration. Timing: administer the peptide stack alongside your antibiotic regimen without adjustment to either protocol.

SOURCE / realpeptides.co ↗
05What If the Infection Site Has Poor Blood Flow?+

Administer BPC-157 first to restore capillary density before adding LL-37. Hypoxic tissue (pO₂ <20 mmHg) reduces LL-37's antimicrobial efficacy because immune cell recruitment depends on vascular access. Preclinical protocols in ischemic wound models use 7–10 days of BPC-157 monotherapy (500 mcg/day subcutaneous) to raise tissue oxygen levels before introducing LL-37. Once pO₂ exceeds 30 mmHg. Verified by transcutaneous oxygen monitoring in research settings. LL-37 demonstrates full biofilm-disrupting activity.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Indications

Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection. Enhanced healing and reduced recovery following crush injuries and surgical procedures with direct tissue targeting. Promotes blood vessel formation and improves vascularization through localized delivery. Protective effects against neurotoxic agents and ischemic brain injury models. Improved functional recovery and reduced tissue damage in spinal cord injury studies. Enhanced peripheral nerve regeneration and functional recovery after injury. Protective effects against gastric and duodenal ulcers through cytoprotective mechanisms. Acceleration of intestinal healing with reduced inflammatory markers in IBD models. Enhanced mucosal barrier function and accelerated epithelial regeneration.

RESEARCH

BPC-157 Tissue Repair Research Across Tissue Types

While the BPC-157 throat spray format targets the upper GI tract, the broader BPC-157 research literature spans many tissue types. Research has documented BPC-157 effects on tendon, ligament, muscle, and gastrointestinal tissue repair, alongside the nitric oxide system modulation and angiogenesis mechanisms described earlier. This breadth of documented tissue effects is part of why BPC-157 is one of the most-studied research peptides. PubMed research on BPC-157 tendon healing indexes part of this literature. For the throat spray format specifically, the relevant tissue research concerns the upper digestive and oropharyngeal tissues. But understanding the broader tissue-repair research provides context for why researchers study BPC-157 across so many delivery routes. The compound’s documented mechanisms — nitric oxide signaling, angiogenesis, growth factor pathways — operate across tissue types, which is why both local and systemic delivery formats are researched. The BPC-157 throat spray is frequently of interest to researchers who also study other delivery formats, because comparing local mucosal delivery to systemic delivery within the same research program can illuminate how delivery route affects outcomes. The BPC-157 vs TB-500 comparison covers how BPC-157 compares to the other major tissue-repair research peptide across these applications.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Studied Stress Fracture: Comparison Across Bone Healing Interventions

BPC-157 (animal models) VEGF upregulation, eNOS activation, MSC recruitment to fracture site 40–60% faster radiographic union in rodent studies Controlled animal trials; no Phase …